MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration (AMD)

Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration (AMD)

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00094120

Enrollment

Registered

2004-10-14

Start date

2004-10-31

Completion date

2007-02-28

Last updated

2008-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Keywords

Age-Related Macular Degeneration - Wet Type

Brief summary

Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - dry and the more severe wet form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with wet AMD.

Interventions

DRUGMSI-1256F (Squalamine Lactate)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with a diagnosis of wet age-related macular degeneration

Exclusion criteria

* Prior treatment for wet age-related macular degeneration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026